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Abstract
Background: The World Health Organization recommends artemisinin-based combination (ACT) for the treatment
of uncomplicated malaria. Post-licensure safety data on newly registered ACT is critical for evaluating their risk/
benefit profile in malaria endemic countries. The clinical safety of the newly registered combination, Eurartesim®,
following its introduction into the public health system in four African countries was assessed.
Methods: This was a prospective, observational, open-label, non-comparative, longitudinal, multi-centre study
using cohort event monitoring. Patients with confirmed malaria had their first dose observed and instructed on
how to take the second and the third doses at home. Patients were contacted on day 5 ± 2 to assess adherence
and adverse events (AEs). Spontaneous reporting of AEs was continued till day 28. A nested cohort who completed full
treatment course had repeated electrocardiogram (ECG) measurements to assess effect on QTc interval.
Results: A total of 10,925 uncomplicated malaria patients were treated with Eurartesim®. Most patients,95% (10,359/
10,925), did not report any adverse event following at least one dose of Eurartesim®. A total of 797 adverse events were
reported. The most frequently reported, by system organ classification, were infections and infestations (3. 24%) and
gastrointestinal disorders (1. 37%). In the nested cohort, no patient had QTcF > 500 ms prior to day 3 pre-dose 3. Three
patients had QTcF > 500 ms (509 ms, 501 ms, 538 ms) three to four hours after intake of the last dose. All the QTcF
values in the three patients had returned to <500 ms at the next scheduled ECG on day 7 (470 ms, 442 ms, 411
ms). On day 3 pre- and post-dose 3, 70 and 89 patients, respectively, had a QTcF increase of ≥ 60 ms compared
to their baseline, but returned to nearly baseline values on day 7.
Conclusion: Eurartesim® single course treatment for uncomplicated falciparum malaria is well-tolerated. QT interval
prolongation above 500 ms may occur at a rate of three per 1,002 patients after the third dose with no association of
any clinical symptoms. QT interval prolongation above 60 ms was detected in less than 10% of the patients without
any clinical abnormalities.
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Background
The World Health Organization (WHO) recommends
artemisinin-based combination therapy (ACT) for the
treatment of patients with uncomplicated malaria [1]. In
controlled trials in Africa, ACT has been found to be gen-
erally safe [2-10]. In October 2011, the European Medi-
cines Agency (EMA) approved a new ACT, Eurartesim®,
for the treatment of uncomplicated malaria caused by
Plasmodium falciparum [11]. Eurartesim® is a fixed-dose
combination of dihydroartemisinin (DHA) and pipera-
quine phosphate (PQP) in film-coated tablets. DHA is a
fast acting anti-malarial and PQP is an orally active bisqui-
noline, structurally related to chloroquine, highly lipo-
philic with a half-life of about 22 days [12,13].
A high treatment success (>95%) with Eurartesim® was
demonstrated in pivotal trials conducted in Africa and
Asia, but in some studies electrocardiogram (ECG) mon-
itoring showed a prolonged QTc interval in some pa-
tients. Some other anti-malarials have also been shown
to produce a transient prolongation of QT interval during
treatment, without significant clinical relevance to the pa-
tient [14-16]. At the time of registration of Eurartesim®,
the Committee for Medicinal Products for Human Use
(CHMP) of EMA considered that the safety database for
the drug was insufficient to determine the frequency of
QT prolongation and the risk of arrhythmias after
taking Eurartesim®, though non-clinical data showed
the torsado-genic cardiotoxicity of Eurartesim®to be
lower than that of chloroquine and similar to that of
mefloquine and artemether + lumifantrine [17,18]. As
part of the post-registration requirements, EMA re-
quested a risk management plan, including safety data
from a phase IV safety study. Such post-licensure data
were considered important for evaluating the risk/
benefit profile of the drug to inform decisions on the
use of the drug by policy makers, globally and at na-
tional levels. The requested Phase IV study has been
conducted by the INDEPTH Effectiveness and Safety
platform (INESS) [19].
The INDEPTH effectiveness and safety study (INESS)
platform
The INESS platform was set up in 2009 to facilitate the
conduct of large phase IV studies of newly registered anti-
malarials in Africa, to provide timely country-specific safety
and effectiveness data to assist in the formulation of na-
tional and global policies. The platform comprises eight
Health and Demographic Surveillance Sites (HDSS) of the
INDEPTH Network in four African countries (Rufiji and
Ifakara in Tanzania, Nouna and Nanoro in Burkina Faso,
Navrongo, Kintampo and Dodowa in Ghana and Manhica
in Mozambique). All four countries are official members of
the WHO pharmacovigilance programme, with estab-
lished spontaneous reporting systems, although the
reporting rates are very low. An independent scientific
review committee oversees the scientific activity of
INESS. Prior to the introduction of Eurartesim, data
collection for patients prescribed available anti-
malarials had been ongoing on the platform, using
structured questionnaires adapted from the national
spontaneous reporting form for the collection of ad-
verse events (AE) after drug treatment, with support
from the WHO Collaborating Centre for Advocacy and
Training in Pharmacovigilance. This study presents the
initial findings of the safety of Eurartesim® following its
introduction into the four African countries.
Methods
Study setting
The study protocol was approved by an Independent
Scientific Review Panel composed by experts in pharma-
covigilance, tropical medicine and statistics. The study
was conducted in seven HDSS (Rufiji, Nouna, Nanoro,
Navrongo, Kintampo, Dodowa and Manhica), with an
estimated total population under demographic surveil-
lance of about 750,000. Malaria is endemic in all the
sites, with P falciparum accounting for more than 90%
of malaria infections. At the time of the study, the first-
line drugs for uncomplicated malaria in these countries
were artesunate + amodiaquine and artemether + lume-
fantrine, and in Ghana, also DHA + PQP. In Tanzania,
DHA + PQP is recommended as the first-line alternate
[20-26].
Study design
The study was designed as a cohort event monitoring
(CEM) study - a prospective, observational, open-label,
non-comparative, multi-centre study. All patients visit-
ing the 41 selected health facilities were screened by a
health worker for malaria symptoms (presence or history
of fever within two days, chills, headache, general mal-
aise and loss of appetite), and malaria was diagnosed
using an approved malaria rapid diagnostic test (RDT),
as per the national guidelines and recommended by
WHO. An eligible patient (or their guardian) was invited
to participate in the study after uncomplicated malaria
was diagnosed and signed informed consent or assent
(for children between age 12 and 18 years) was obtained.
Eligible patients were aged over six months, weighed
more than 5 kg and were able to take oral medications.
Patients were excluded if they had any of the following:
intake of DHA/PQP in the previous four weeks; known
allergy to artemisinin or piperaquine; known to be preg-
nant or lactating; severe or complicated malaria; taking
medicinal products that prolong the QTc interval, in-
cluding antiarrhythmics and neuroleptics; family or per-
sonal history of cardiac arrhythmia/QT prolongation
(including congenital long QT syndrome, arrhythmia),
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and family history of sudden unexplained death. Also
patients were excluded from the ECG sub-study (see
below) if they had QTc interval greater than 450 milli-
seconds, with either Bazett or Fridericia correction, in
the initial ECG.
Enrolment and study procedure
Each eligible participant had a detailed clinical examin-
ation and any significant medical history was recorded.
A microscopic slide for malaria parasites was prepared,
time of intake of the last meal was recorded and case
report forms (CRF) were corrected. For eligible
patients, the first dose of Eurartesim® was administered
with water under supervision by a study staff member.
The patient was observed for about an hour for any
AE. During this time, the patient was encouraged not
to eat any fatty or high calorie foods. Patients were
instructed to take the remaining two doses at home
with water on days 2 and 3, about three hours before
or after meals. Patients were taught how to use diary
cards and instructed how to document time and type of
food before and after intake of the remaining two doses.
Each patient was included once in the study. Patients who
vomited within 30 minutes of administration of the first
dose were re-treated with the same dosage, and if vomit-
ing occurred within 30 to 60 minutes, half a dose was re-
administered. Re-dosing was not attempted more than
once. Dosing was in four weight bands as shown in Table 1.
Pregnancies discovered within 28 days of Eurartesim® in-
take were followed at least every three months and after
delivery up to 14 weeks to assess pregnancy outcome.
Patients who, in addition, consented to be part of a
nested cohort was selected if QTcF interval was less
than 450 ms and had an intensive laboratory assess-
ment, samples for pharmacokinetic analysis. A series
of ECGs monitoring at the baseline (day 1 pre-dose 1),
day 3 pre-dose 3, day 3 post-dose 3 and on day 7 at the
health facility. The first dose of Eurartesim® was given
at the clinic also under “Direct Observed Treatment”
three hours before or after meals and observed for an
hour. Dose 2 was taken at home and dose 3 at the
health facility.
Follow-up for any adverse events
All patients had a scheduled follow up on day 5 (±2 days)
either by telephone or by a visit, by field supervisors or
health agents trained by the research team to solicit AE.
Record was made of whether any symptoms of malaria
remained and of any AE that had occurred since Eurarte-
sim® was administered. Patients were contacted again on
day 28 to ascertain any further AE. Patients who had any
medical event of concern, or whose symptoms worsened
between intake of the first dose and within 28 days of in-
take of Eurartesim®, were asked to visit the nearest health
facility or to immediately contact the site investigators,
using the telephone numbers on the consent form. If any
patient reported a cardiac event, an ECG was performed
and the trace was inspected for QTc prolongation or other
abnormalities. Any patient reporting an adverse event
deemed to be serious was given recommended care in line
with the national standard in that country. Each site had a
local pharmacovigilance monitoring committee, which
regularly reviewed the listings of AE collected during the
study. They also received notification of serious adverse
events (SAE), adverse events of special interest (cardiac
toxicity, neurological toxicity and photo-toxicity) and all
AE classified as severe. These committees were charged
with identifying possible safety signals and communicating
any such signals immediately to the study investigators.
National regulatory authorities and ethics committees
were also notified of any AE classified as serious.
Nested cohort
ECG recording and interpretation
Patients in the nested cohort had more detailed investiga-
tions, primarily to assess any effect of Eurartesim® on the
QTc interval duration. Blood samples were also taken for
pharmacokinetic studies. After clinical examination, all pa-
tients in the nested cohort had baseline ECGs, in triplicate,
using 12-leads digitalized ELI 150 Cardiograph®. Tracings
were done at least three hours before or after food intake
and the three recordings were taken in a quiet room, with
an interval between the readings of 1 to 2 minutes. ECGs
were read by trained and ECG-certified study clinicians (by
Cardiabase) before the first dose of Eurartesim® was
Table 1 Doses of Eurartesim® administered according to patient weight
Body weight (kg) Daily dose (mg) Number of tablets per dose
20/160 mg DHA/PQ 40/320 mg DHA/PQ
5-12 20/160 mg DHA/PQP 1
13-23 40/320 mg DHA/PQP 1
25-35 40/320 mg DHA/PQP 2
36-74 40/320 mg DHA/PQP 3
>74 40/320 mg DHA/PQP 4
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administered. The QTcF was automatically calculated and
manually verified by the study clinician. Participants with
an average QTcF of ≥ 450 ms were excluded from the study
and prescribed alternative anti-malarial medicines, as per
the national guidelines. Electronic copies of all ECGs were
sent to the Cardiabase laboratory in France [27] for inter-
pretation by a certified cardiologist. Study clinicians notified
Cardiabase regarding any patients for whom ECG reports
were required within 24 hours for purposes of clinical man-
agement. A further ECG was done immediately prior to
dose 3 of Eurartesim® and pharmacokinetic (PKa) blood
samples were taken before the day 3 dose was administered.
The patients were observed for three to four hours after
dose 3 and then post-dose three ECGs (triplicate) were per-
formed, followed by collection of PKa blood samples. Par-
ticipants whose pre-dose 3 QTc interval was ≥ 500 ms were
observed for six hours and ECGs were repeated until the
QTc interval was less than 480 ms before the third dose
was administered. Alternative anti-malarial medicines were
administered if the QTc interval persistently remained
above 480 ms. On day 7, ECGs were repeated for each
participant.
Reading of the set of ECGs for a given patient was per-
formed by the same cardiologist. The reader was blinded
with respect to the timing and the day of the ECG re-
cording. A computer-assisted, semi-automatic, on-screen
measurement of the digital ECG waveform was used for
the reading (ECG Manager©). The QT interval measure-
ment was edited from the global superimposed median
beats. Each median beat was mathematically derived
from the available recording of the corresponding lead.
The 12 individual median beats were graphically dis-
played as temporally aligned and overlapped one to an-
other. Global interval measurement was subsequently
defined as the interval from the earliest onset observed
on any of the 12 superimposed lead to the latest offset
observed on any of the 12 leads, in accordance with the
American College of Cardiology/American Heart Asso-
ciation recommendations. Quality control checks of the
readers were conducted during the study, including the
assessment of the intra-reader and inter-reader variabil-
ity, to assure the quality of the results. Copies of all ECG
confirmed reports were sent back to the study clinicians
and stored in the central database.
Outcome
The main outcome of interest was clinical safety evalu-
ated through the analysis of AE after administration of
Eurartesim® treatment, including AEvidentified in the re-
ferring health facilities or spontaneously reported by the
patients as occurring within 28 days after the first medi-
cation . In the nested cohort, cardiotoxicity from ECG
findings (QT corrected by Fridericia”s formula) was the
main safety outcome. AE of special interest (AESI) –
relating to cardiotoxicity - were also an outcome of inter-
est in both groups.
Sample size
It was planned to collect data on Eurartesim® treatment
of approximately 10,000 cases of uncomplicated malaria.
This number of cases allowed identification of at least
one AE occurring at a frequency of one in 3000 with a
95% probability. In the nested cohort, a sample of 1,000
gave a probability of 0. 865 of observing at least one car-
diac event of interest (i. e. palpitations, fainting/syncope,
pounding/pain in the chest area, seizures) that might be
related to QT interval prolongation, assuming the true
rate was at least 3/1,000.
Data entry and statistical analysis
Data were double-entered and verified using OpenClinica
software. Statistical analyses were performed using the soft-
ware package STATA® (version 11. 2). Descriptive analyses
were conducted of all data recorded at study entry. AEs
were documented as described by the participant or care-
giver, reviewed and coded using version 13. 1 of the
Medical Dictionary for Regulatory Activities (MedDRA®).
All events reported were grouped by MedDRA® System
Organ Class (SOC) classification. The estimates of the inci-
dence of AEs were based on crude rates, with no attempt
to carry out causality assessment of individual cases. In the
nested cohort, the QTc interval was evaluated after correct-
ing for the heart rate with Fridericia’s formula (QTcF =QT/
RR1/3). Descriptive analysis of the mean QTcF was done
and the mean difference between the baseline and day 3
pre-dose, day 3 post-dose and day 7 was computed. The
primary outcome of interest was QTcF > 500 ms after in-
take of the first dose of Eurartesim® or a change of QTcF
(ΔQTcF) ≥ 60 ms from baseline at each scheduled ECG. Pa-
tients who had increased QTcF (≥500 ms), or a prolonged
interval of more than 60 ms at any point of their scheduled
ECG, were followed through today 7 for QTc outcome
[28,29]. Blood biochemistry and pharmacokinetic sample
analysis will be presented elsewhere.
Ethics
Written informed consent was obtained from all patients
before performance of any study-related activity. The
protocol was approved by the national ethics committees in
Ghana, Burkina Faso, Tanzania and Mozambique and insti-
tutional review boards at each participating site. The study
was registered with Clinicaltrials. gov (NCT02199951) prior
to enrolment of the first subject.
Results
Cohort composition
11,097 patients with uncomplicated malaria were screened
over a period of 10 months, (September 2013 to June 2014)
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and 11,028 were enrolled. 9,723 (88%) were recruited into
the main study and 1,305 (12%) into the nested cohort
(Figure 1). 96 patients (0. 9%) were lost to follow-up with
no information after intake of the first dose at the health fa-
cility and seven children were withdrawn, being under six
months old. Sixty-one patients in the main study did not
complete the full course of Eurartesim® over the three day
period due to vomiting after re-dosing on day 1 (43) or
worsening of their presenting symptoms (18).
In the nested cohort, 273 patients were not included
in the analysis. Eleven had baseline mean QTcF > 450 ms,
262did not have either the required number of eight ECGs
(triplicate on day 1, single on day 3 pre-dose 3, triplicateon
day 3 post-dose 3 and a single ECG on day 7) or the
required four PKa samples.
Participants with complete treatments and study
procedures
10,591 (1,002 in the nested cohort) completed a full course
of Eurartesim® over a three-day period and had complete fol-
low up (Figure 1). The largest number of patients was re-
cruited in Ghana, followed by Burkina Faso, Mozambique
and Tanzania (Table 2). About half of the patients were male
and about half were under the age of six years. Plasmodium
falciparum infection was diagnosed by RDT in all except 30
patientswho were diagnosed according toWHO recommen-
dations on presumptive diagnosisof malaria. 7,391 had
microscopic slide reading, and, of these, 44% had parasite
densities in excess of 5,000/μL. Sixty-four percent (6,807) of
patients received concomitant medications mainly analge-
sics (56%) and haematinics (15%) (Additional file 1). Sixty-
six percent were followed up on day 5 ± 2 person and the
rest by telephone. On day 28, 61% were followed up at home
and the remainder by phone contact.
AEs and AESIs reported
Most patients, 95% (10,359/10,925), who received at
least one dose of Eurartesim® did not report any adverse
event. 566 patients reported a total of 797AEs, of which
32 were classified as serious (SAEs). The most fre-
quently reported events, classified by SOC allocation,
were infections and infestations (3. 24%), gastrointes-
tinal disorders (1. 37%), general disorders and adminis-
trative site conditions (0. 76%) and respiratory, thoracic
and mediastinal disorders (0. 5%) (Table 3). MedRA classi-
fication by preferred term is as shown in Additional file 2.
AESI mainly reported under cardiac disorders, were
four instances of palpitations and a newly diagnosed
Figure 1 Patient flow.
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case of hypertension (0. 05%) and 26 instances (0. 24%)
of skin and subcutaneous tissue disorders, with half
presenting with pruritus. Fifty (0. 46%, including 31 epi-
sodes of headache, were reported under nervous system
disorders. AEs by study site ranged from 46 to 134 per
1000 with Rufiji reporting the highest rate (Additional
file 3).
Of the 32 SAEs reported, 18 (56%) were in partici-
pants aged < six years. Six deaths occurred during the
study (two each from Ghana and Tanzania, one each
from Burkina Faso and Mozambique) (Additional file 4).
Details of these deaths are given below:
 A 17-month old boy who was treated with Eurarte-
sim® presented after two weeks with severe dehydra-
tion, secondary to acute gastroenteritis. He died
within 24 hours of admission. No autopsy was
undertaken. The death was assessed as unlikely to be
related to intake of Eurartesim®.
 A 5-yearold male who died at home on the 3rd day
after treatment. Verbal autopsy suggested probable
hypoglycaemia. Severe malaria could not be ruled
out. The death was assessed as unrelated to intake
of Eurartesim.
 A22-year old female who had intractable vomiting
immediately the first dose of Eurartesim® was
administered. She was managed as a case of
uncomplicated malaria and acute hepatitis B
infection with complication of liver failure. No
autopsy was performed. The death was assessed as
unrelated to intake of Eurartesim.
 A4-year old female who presented as a case of
uncomplicated malaria and was treated with
Eurartesim® on an out-patient basis. Her condition
deteriorated at home and she presented again within
24 hours of recruitment at the health facility with
severe anaemia. She died on the way to a higher
referral facility for blood transfusion. No autopsy
Table 2 Demographic and baseline clinical characteristics of participants who took all the three doses of Eurartesim®
and completed study procedures
Main study Nested cohort Total n (%)
Variable N = 9,589 1,002 10,591
Country (n (%))
Burkina Faso 2,718 (28. 3) 299 (29. 8) 3,017 (28. 5)
Ghana 4,119 (43. 0) 444 (44. 3) 4,563 (43. 1)
Mozambique 1,876 (19. 6) 89 (8. 9) 1,965 (18. 6)
Tanzania 876 (9. 1) 170 (17. 0) 1,046 (9. 9)
Gender (n (%))
Female 5,068 (52. 8) 519 (51. 8) 5,587 (52. 7)
Male 4,521 (47. 2) 483 (48. 2) 5,004 (47. 3)
Age group (n (%))
<6 4,654 (48. 5) 331 (33. 0) 4,985 (47. 1)
6 - <13 2,612 (27. 2) 398 (37. 7) 3,010 (28. 4)
13- <18 753 (7. 8) 112 (11. 2) 865 (8. 2)
>18 1,570 (16. 4) 161 (16. 1) 1,731 (16. 3)
Plasmodium positivity (n (%))
RDT only 3,170 (33. 0) - 3,170(29. 9)
Microscopy only 1,405 (14. 6) 274 (27. 4) 1,679 (15. 9)
Both RDT and microscopy 4,984 (52. 0) 728 (72. 6) 5,712(53. 9)
Presumptive diagnosis 30 (0. 3) - 30 (0. 3)
*Parasite density (/μL) (P. falciparum) *(n (%))
No parasite observed 37 (0. 6) 8 (0. 8) 45 (0. 6)
<50 421 (6. 6) 80 (8. 0) 501 (6. 8)
50- < 500 1,282 (20. 1) 214 (21. 5) 1,496 (20. 3)
500- < 5,000 1,800 (28. 3) 265 (26. 6) 2,065 (28. 0)
5000- < 50,000 1,477 (23. 2) 268 (26. 9) 1,745 (23. 7)
≥50,000 1,354 (21. 2) 160 (16. 1) 1,514 (20. 6)
*25 patients had other species of Plasmodium that was not falciparum.
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was performed and the death was assessed as un-
likely to be related to intake of Eurartesim®.
 A26-year old female, known to be HIV-infected who
died of HIV vasculitis on the 3rd day of treatment
with Eurartesim®. The death was assessed as unrelated
to intake of Eurartesim®.
 A3-year old female who died at home on the 3rd
day after recruitment. Verbal autopsy suggested
severe malaria. The death was assessed as unlikely to
be related to intake of Eurartesim®.
Nested cohort
A total of 1,002 patients completed three doses of Eurar-
tesim® and had complete cardiac monitoring. The mean
QTcF at baseline was 393. 7 ms. On day 3 pre-dose 3,
the mean QTcF (411. 2 ms) increased by 18 ms (95% CI
16,19) from the baseline and on day 3 post-dose 3 (415.
8 ms) by 23 ms (95% CI 21,24) from the baseline. On
day 7, the mean QTcF (398. 6 ms) had returned to near
the baseline value, with a mean difference of 5. 4 ms,
(95% CI 4, 7) (Table 4). The findings were similar for
QTcB (QT corrected by Bazett’s formula).
QTcFof greater than 500 ms following treatment
No patient had QTcF greater than 500 ms prior to treat-
ment or on day 3 pre-dose 3. On day 3 post-dose (three
to four hours after administration of Eurartesim®) three
male patients, aged 8, 19 and 24 years had a mean QTcF
of more than 500mswith the following values; 509 ms,
501 ms, 538 ms respectively. All QTcF values in the
three patients were less than 500 ms on day 7 (470 ms,
442 ms, and 411 ms, respectively). Since no other ECGs
were conducted between days 3 and 7, the time during
which the QTcF value was above 500 ms is not known.
Two female patients, aged 62 and 41 years, whose
QTcF were less than 500msat baseline, on day 3 pre and
post dose 3, had a QTcF > 500 ms (501 ms and 532 ms)
on day 7. No clinical symptoms or signs were reported
during the follow up of these patients and no other
ECGs were performed.
Increase in QTcFof more than 60 ms from baseline on day
3 pre-dose 3
On day 3 pre-dose three, 70 patients had an increase in
the QTcF interval of more than 60 ms compared to their
baseline measurement. Sixty-five of these (93%) were
children under 12 years old. The oldest person was
27 years. The range of prolongation was 60 to 144 ms.
On day 7, in all 70 patients, the mean QTcF interval was
less than 60 ms above their baseline measurements –
the average increase was 37. 7 ms in males and 27. 9 ms
in females.
Table 3 Incidence rate of events reported by system organ classification (grouped by MedDRA® coding) in the total
cohort (N = 10,925)
MedDRA® System organ classification Number of events, (n) Incidence rate per 1,000 (n/N)
Blood and lymphatic system disorders 15 1. 4
Cardiac disorders 5 0. 5
Congenital, familial and genetic disorders 3 0. 3
Ear and labyrinth disorders 2 0. 2
Eye disorders 8 0. 7
Gastrointestinal disorders 150 13. 7
General disorders and administrative site conditions 83 7. 6
Immune system disorders 1 1. 0
Infections and infestations 354 32. 4
Injury, poisoning and procedural complications 5 0. 5
Metabolism and nutrition disorders 14 1. 3
Musculoskeletal and connective tissue disorders 12 1. 1
Nervous system disorders 50 4. 6
Pregnancy, puerperium and perinal conditions 1 0. 1
Psychiatric disorders 4 0. 4
Renal and urinary disorders 2 0. 2
Reproductive system and breast disorders 2 0. 2
Respiratory, thoracic and mediastinal disorders 59 5. 4
Skin and subcutaneous tissue disorders 26 2. 4
Other 1 0. 1
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On day 3 post-dose 3, 89 patients had a QTcF interval
of more than 60 ms compared to their baseline. Forty-one
of these also had a prolonged QTcF on day 3 pre-dose 3.
There was a significant difference in the mean change of
QTcF prolongation between males and females (8. 3 ms,
95% CI: 1. 1, 15. 6). 84% (75/89) were under 12 years old
and the maximum age was 37 years. The mean QTcF re-
duced to 31 ms in both sexes on day 7.
On day 7, seven patients (0.7%) had aQTc interval
more than 60 ms above their baseline. Five patients did
not have prolongation on day 3 (pre and post dose).
Two of the seven patients on day 7, (0.2%) persistently
had prolongation of more than 60 ms from day 3 pre-
and post- dose. None of the two patients had QTcF
readings of more than 500 ms.
Discussion
This study used CEM, with a very high follow-up rate
(>95%) by either home visits or by telephone. Eurartesim®
was well tolerated and there was a relatively low rate of
AE, 7.3%, of mild or moderate severity. The rate of re-
ported AE in this study was lower than those reported in
the previous phase III trials, conducted both in African
and Asian populations [14,15,30]. ACT is widely being
deployed in endemic countries and used both under pre-
scription and over the counter, and they appear to have a
good tolerability. It is not surprising that using a study
design simulating the real condition of use, a lower inci-
dence of AE has been reported than in Phase II-III clin-
ical trials, in which usually the anxiety of the patient
taking a new drug and the blinded condition in which
such drugs are administered may cause an increase of AE
reporting. This study demonstrates that a large cohort of
patients with confirmed uncomplicated malaria had min-
imal safety concerns with most events reported being
related more to malaria than to intake of Eurartesim®.
This provides a significant assurance of the tolerability of
Eurartesim® as assessed in real-life conditions in four
African countries with patients taking not just the anti-
malarial but also other concomitant medications as well.
PQP belongs to the class of bisquinolones, which has
been documented to prolong electrocardiographic QT
interval and may have significant clinical effect in sus-
ceptible individuals. The aim of this study was also to
include a nested population of about 1,000 patients, se-
lected according to the ECG criteria, used in previous
clinical trials, in which this interval was evaluated in
healthy volunteers, to compare the results obtained in
this patient population with those obtained in healthy
volunteers when a full course of Eurartesim® was admin-
istered. The only difference between the nested popula-
tion and the general population was the exclusion of
patients in which baseline QTcF interval was found to
be higher than 450 ms. This exclusion criterion was
adopted in the selection of the nested population to
maintain enrolment criteria similar to those applied to
the healthy volunteers in previous studies, in order to
be sure to have comparable ECG inclusion criteria. This
criterion excluded only 11 out of 1305 patients re-
cruited; therefore this criterion did not really have any
impact on selecting a different population in the nested
group respect to the general population. The results
confirmed that transient prolonged QTcF after intake of
Eurartesim® was more common in children less than
12 years and peaked on day 3 when the maximal drug
concentration is expected, returning to almost baseline
values within four days (day 7 visit). However this
period also coincides with the acute period of malaria
where evidence of prolongation has been documented
[16]. The analysis of the relationship of the time of drug
administration with the food intake and concomitant
medication will be published after pharmacokinetic ana-
lysis. Two cases recorded with increased QTcF > 500 ms
on only day 7 may be due to increased heart rate and
overestimation of the QT interval or to the influence of
the circadian rhythm on QT interval correlated with the
different times of ECG collection on day 1,3 and day 7.
Table 4 ECG summary parameters (means in ms) for day 1, day 3 pre-dose, day 3 post-dose and day 7 for treatment
with three doses of Eurartesim® [N = 1,002] based on central laboratory readings
PR HR QT QTcB QTcF 95% *Confidence interval *P-value
Visit
Day 1 (baseline) 134. 2 104. 6 331. 9 429. 6 393. 3 - -
Day 3 pre-dose 3 138. 3 92. 5 355. 4 434. 2 411. 2 - -
Day 3 post-dose 3 140. 5 91. 6 366. 1 444. 1 415. 8 - -
Day 7 137. 6 94. 2 346. 2 428. 2 398. 6 - -
Δ Days 1 to 3 pre-dose 4. 1 −12. 1 23. 5 4. 6 17. 9 16 ,19 <0. 001
Δ Days 1 to 3 post-dose 6. 3 −13. 1 34. 2 14. 6 22. 5 21,24 <0. 001
Δ Days 1 to 7 3. 3 −10. 3 14. 2 -. 31 5. 3 4,7 <0. 001
*Confidence intervals and *P-values were calculated for the mean change in QTcF.
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There was no documentation of clinically relevant cardiac
toxicity and no episodes of torsade de pointes or ventricular
fibrillation or flutter. This adds to the evidence that a single
course of Eurartesim® is safe at therapeutic doses for treat-
ing uncomplicated malaria. However, safety data on re-
peated treatment courses is limited and there might be a
potential risk of piperaquine accumulation [31]. Analysis on
the biochemical parameters and plasma level concentration
of the drug to relate to the QT findings and AE will be pub-
lished in a subsequent paper. In addition, detailed analysis
of the safety data including causality assessment of AE will
be undertaken.
This study represents, by far, the largest and most
rigorously conducted phase IV assessment of any anti-
malarial medicine in real-life conditions in Africa. Pre-
vious studies have been limited in terms of numbers
[5,6]. This phase IV study of Eurartesim®, carried out
relatively quickly after licensure of the drug by the
EMA, as part of the risk management plan for Eurar-
tesim®, demonstrates the possibility of undertaking
rigorous safety assessment of anti-malarials in real-life
settings in malaria-endemic countries. It has produced
data that will be contributed to the WHO Programme
for International Drug Monitoring and provides useful
information for national malaria control programmes
that are considering including Eurartesim® as part of
their first line treatment of uncomplicated malaria.
Together with data from INESS collected since 2009 and
on amodiaquine + artesunate (Ghana) and artemether +
lumefantrine (Tanzania), this study highlights the usefulness
of the INESS platform as an African-led, rigorous scientific
platform, working with global partners, to assess the safety
and effectiveness of anti-malarial medicines and to pro-
vide information on the data collected in a timely manner
to all partners.
Challenges and limitations
There was a delay in initiating the studies due to the
long time interval between the submission of the dossier
for registration and approval from the various national
regulatory authorities. Missed visits or incomplete data
created some gaps in collecting information but this was
low (<5%) and did not affect the results overall. This was
an observational study with no blinding of investigators
and participants, therefore, there may have been a ten-
dency to report adverse effects for which symptoms pre-
sented at the health facility before treatment as AE
which were not “new or worsening events” post-
treatment. Another limitation of the study is the incap-
ability to closely estimate the exact QTcF prolongation
time shown by some patients in the nested group, with
no ECG recordings between days 3 and 7. The repeated
blood draw and long waiting time by study participants
to complete study procedures in the nested cohort was
difficult for sites which were semi-urban, but this was
balanced by provision of snacks and meals three to four
hours after administration of the drug, ECG procedure
and collection ofPKa samples. Re-imbursement of trans-
portation cost and free medical care during the 28 days of
participation in the study were also an incentive.
Conclusion
The study demonstrated that it is feasible to conduct
post-licensure safety monitoring of more than 10,000
confirmed malaria patients, including ECG monitoring,
of a newly registered anti-malarial, using CEM, as part
of pharmacovigilance activities in both rural and semi-
urban setting in Africa. The study showed Eurartesim®
to be a well-tolerated anti-malarial medicine from the
initial analysis though transient QTc prolongation may
occur in children under 12 years of age, comparable
findings in phase III studies carried out in Africa [14].
This will be analysed further in subsequent papers with
availability of pharmacokinetic data and relationship of
food intake with the drug. The INESS platform is rigor-
ous and functional and can be used for future drugs and
vaccines safety assessment for phase IV studies in
Africa.
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